Lumicell, a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, announced the U.S. commercial availability and first commercial use of LumiSystem. This groundbreaking system combines two recently FDA-approved products: LUMISIGHT, an optical imaging agent that fluoresces at sites of suspected cancerous tissue, and Lumicell Direct Visualization System (DVS), an imaging device that provides real-time fluorescence guidance for scanning the breast cavity during lumpectomy surgery.
Health Technology Insights: OnDoc.ai and Valet Health Partner to Revolutionize Patient Education with Physician Avatars
Unlike other detection systems that only evaluate tissue after it has been surgically removed, LumiSystem allows for real-time visualization of cancer inside the breast. This enables surgeons to identify and immediately resect any suspicious tissue during the surgery, improving the likelihood of achieving a more complete resection and reducing the need for follow-up procedures.
“We breast surgeons know all too well the limitations of lumpectomy and the difficult conversations we have with patients about the possibility of a second surgery due to positive margins,” said Irene Wapnir, MD, Professor of Surgery at Stanford University School of Medicine and Director of Breast Cancer Surgical Clinical Research at the Stanford Cancer Institute. “Stanford is excited to adopt LumiSystem because, with its real-time fluorescence guidance, we are now able to detect and remove more cancerous tissue during surgery while still sparing as much healthy breast tissue as possible.”
Health Technology Insights: JPA Health Launches Investor Relations Practice, Expanding Suite of Services
With 84% diagnostic accuracy, LumiSystem improved surgical outcomes in 10% of patients treated in the INSITE pivotal trial.1-2 By identifying cancerous tissue completely missed by surgeons and pathologists, LumiSystem offers a more comprehensive approach to breast-conserving surgery and ultimately enhances patient care.
“Today, with LumiSystem’s commercial launch, we empower surgeons with a groundbreaking tool that detects cancer where and when it matters most, inside the breast cavity and in real-time,” said Howard Hechler, CEO of Lumicell. “This launch reflects Lumicell’s unwavering commitment to enhancing surgical outcomes for patients.”
Health Technology Insights: JPA Health Launches Investor Relations Practice, Expanding Suite of Services
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
